Real-world prevalence of PD-L1 expression in non-small cell lung cancer : an Australia-wide multi-centre retrospective observational study
Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved..
An investigator-initiated, Australia-wide multi-centre retrospective observational study was undertaken to investigate the real-world prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung carcinoma (NSCLC). Multiple centres around Australia performing PD-L1 immunohistochemistry (IHC) were invited to participate. Histologically confirmed NSCLC of any stage with a PD-L1 IHC test performed for persons aged ≥18 years between 1 January 2018 and 1 January 2020, and eligible for review, were identified at each centre, followed by data extraction and de-identification, after which data were submitted to a central site for collation and analysis. In total data from 6690 eligible PD-L1 IHC tests from histologically (75%) or cytologically (24%) confirmed NSCLC of any stage were reviewed from persons with a median age of 70 years, 43% of which were female. The majority (81%) of tests were performed using the PD-L1 IHC SP263 antibody with the Ventana BenchMark Ultra platform and 19% were performed using Dako PD-L1 IHC 22C3 pharmDx assay. Reported PD-L1 tumour proportion score (TPS) was ≥50% for 30% of all tests, with 62% and 38% scoring PD-L1 ≥1% and <1%, respectively. Relative prevalence of clinicopathological features with PD-L1 scores dichotomised to <50% and ≥50%, or to <1% and ≥1%, were examined. Females scored ≥1% slightly more often than males (64% vs 61%, respectively, p=0.013). However, there was no difference between sexes or age groups (<70 or ≥70 years) where PD-L1 scored ≥50%. Specimens from patients with higher stage (III/IV) scored ≥1% or ≥50% marginally more often compared to specimens from patients with lower stage (I/II) (p≤0.002). Proportions of primary and metastatic specimens did not differ where PD-L1 TPS was ≥1%, however more metastatic samples scored TPS ≥50% than primary samples (metastatic vs primary; 34% vs 27%, p<0.001). Cytology and biopsy specimens were equally reported, at 63% of specimens, to score TPS ≥1%, whereas cytology samples scored TPS ≥50% slightly more often than biopsy samples (34% vs 30%, respectively, p=0.004). Resection specimens (16% of samples tested) were reported to score TPS ≥50% or ≥1% less often than either biopsy or cytology samples (p<0.001). There was no difference in the proportion of tests with TPS ≥1% between PD-L1 IHC assays used, however the proportion of tests scored at TPS ≥50% was marginally higher for 22C3 compared to SP263 (34% vs 29%, respectively, p<0.001). These real-world Australian data are comparable to some previously published global real-world data, with some differences noted.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Pathology - 55(2023), 7 vom: 13. Dez., Seite 922-928 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Farrall, Alexandra L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
22C3 |
|---|
| Anmerkungen: |
Date Completed 15.12.2023 Date Revised 15.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.pathol.2023.08.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363261699 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363261699 | ||
| 003 | DE-627 | ||
| 005 | 20231227131741.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.pathol.2023.08.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1226.xml |
| 035 | |a (DE-627)NLM363261699 | ||
| 035 | |a (NLM)37833206 | ||
| 035 | |a (PII)S0031-3025(23)00243-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Real-world prevalence of PD-L1 expression in non-small cell lung cancer |b an Australia-wide multi-centre retrospective observational study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2023 | ||
| 500 | |a Date Revised 15.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a An investigator-initiated, Australia-wide multi-centre retrospective observational study was undertaken to investigate the real-world prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung carcinoma (NSCLC). Multiple centres around Australia performing PD-L1 immunohistochemistry (IHC) were invited to participate. Histologically confirmed NSCLC of any stage with a PD-L1 IHC test performed for persons aged ≥18 years between 1 January 2018 and 1 January 2020, and eligible for review, were identified at each centre, followed by data extraction and de-identification, after which data were submitted to a central site for collation and analysis. In total data from 6690 eligible PD-L1 IHC tests from histologically (75%) or cytologically (24%) confirmed NSCLC of any stage were reviewed from persons with a median age of 70 years, 43% of which were female. The majority (81%) of tests were performed using the PD-L1 IHC SP263 antibody with the Ventana BenchMark Ultra platform and 19% were performed using Dako PD-L1 IHC 22C3 pharmDx assay. Reported PD-L1 tumour proportion score (TPS) was ≥50% for 30% of all tests, with 62% and 38% scoring PD-L1 ≥1% and <1%, respectively. Relative prevalence of clinicopathological features with PD-L1 scores dichotomised to <50% and ≥50%, or to <1% and ≥1%, were examined. Females scored ≥1% slightly more often than males (64% vs 61%, respectively, p=0.013). However, there was no difference between sexes or age groups (<70 or ≥70 years) where PD-L1 scored ≥50%. Specimens from patients with higher stage (III/IV) scored ≥1% or ≥50% marginally more often compared to specimens from patients with lower stage (I/II) (p≤0.002). Proportions of primary and metastatic specimens did not differ where PD-L1 TPS was ≥1%, however more metastatic samples scored TPS ≥50% than primary samples (metastatic vs primary; 34% vs 27%, p<0.001). Cytology and biopsy specimens were equally reported, at 63% of specimens, to score TPS ≥1%, whereas cytology samples scored TPS ≥50% slightly more often than biopsy samples (34% vs 30%, respectively, p=0.004). Resection specimens (16% of samples tested) were reported to score TPS ≥50% or ≥1% less often than either biopsy or cytology samples (p<0.001). There was no difference in the proportion of tests with TPS ≥1% between PD-L1 IHC assays used, however the proportion of tests scored at TPS ≥50% was marginally higher for 22C3 compared to SP263 (34% vs 29%, respectively, p<0.001). These real-world Australian data are comparable to some previously published global real-world data, with some differences noted | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 22C3 | |
| 650 | 4 | |a Non-small cell lung carcinoma | |
| 650 | 4 | |a PD-L1 | |
| 650 | 4 | |a SP263 | |
| 650 | 4 | |a prevalence | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a CD274 protein, human |2 NLM | |
| 700 | 1 | |a Farrall, Alexandra L |e verfasserin |4 aut | |
| 700 | 1 | |a Prabhakaran, Sarita |e verfasserin |4 aut | |
| 700 | 1 | |a Asadi, Khashayar |e verfasserin |4 aut | |
| 700 | 1 | |a Barrett, Wade |e verfasserin |4 aut | |
| 700 | 1 | |a Cooper, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Cooper, Wendy |e verfasserin |4 aut | |
| 700 | 1 | |a Cotton, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Duhig, Edwina |e verfasserin |4 aut | |
| 700 | 1 | |a Egan, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Fox, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Godbolt, David |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Shilpa |e verfasserin |4 aut | |
| 700 | 1 | |a Hassan, Aniza |e verfasserin |4 aut | |
| 700 | 1 | |a Leslie, Connull |e verfasserin |4 aut | |
| 700 | 1 | |a Leong, Trishe |e verfasserin |4 aut | |
| 700 | 1 | |a Moffat, David |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Min Ru |e verfasserin |4 aut | |
| 700 | 1 | |a Sivasubramaniam, Vanathi |e verfasserin |4 aut | |
| 700 | 1 | |a Skerman, Joanna |e verfasserin |4 aut | |
| 700 | 1 | |a Snell, Cameron |e verfasserin |4 aut | |
| 700 | 1 | |a Walsh, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Whale, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Klebe, Sonja |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pathology |d 1969 |g 55(2023), 7 vom: 13. Dez., Seite 922-928 |w (DE-627)NLM000008656 |x 1465-3931 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2023 |g number:7 |g day:13 |g month:12 |g pages:922-928 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.pathol.2023.08.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2023 |e 7 |b 13 |c 12 |h 922-928 | ||